Warning over pharmacist substitution of insulin

Diabetes groups have issued a strong warning on PBS moves to allow pharmacists to substitute biosimilar insulins, saying it could lead to serious disruption of diabetes control.

The Australian Diabetes Society has joined with other diabetes groups in issuing a warning to the PBS not to proceed with plans to allow pharmacy-level substitution of insulin glargine.

In March, the Pharmaceutical Benefits Advisory Committee recommended the new insulin glargine product, Basaglar receive PBS listing and said consideration should also be given to allow pharmacy-level substitution with the biosimilar product, Lantus.